Full Press Release Details
SAN FRANCISCO , March 14, 2022 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) will hold an analyst and investor conference call with Nektar management today, Monday, March 14, 2022 , at 5:00 a.m. Pacific Standard Time (PST), following this morning's update from Bristol-Myers Squibb and Nektar on the pivotal Phase 3 PIVOT IO-001 study in previously untreated unresectable or metastatic melanoma.
The press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: http://ir.nektar.com/ . The web broadcast of the conference call will be available for replay through April 15, 2022 .
To access the conference call, follow these instructions:
Dial: (877) 881-2183 (U.S); (970) 315-0453 (international) Conference ID: 9853125 (Nektar Therapeutics is the host)
About Nektar Therapeutics Nektar Therapeutics is a biopharmaceutical company with a robust, wholly owned R&D pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. Nektar is headquartered in San Francisco, California , with additional operations in Huntsville, Alabama and Hyderabad, India . Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com .
For Investors: Vivian Wu of Nektar Therapeutics 628-895-0661
SOURCE Nektar Therapeutics